Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Ganglioneuroblastoma × fludarabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 35 Multiple Myeloma 27 Leukemia, Lymphocytic, Chronic, B-Cell 27 Recurrence 26 Lymphoma, Non-Hodgkin 24 Lymphoma 20 Neoplasms 16 Lymphoma, Large B-Cell, Diffuse 16 Lymphoma, Follicular 14 Lymphoma, B-Cell 14 Precursor Cell Lymphoblastic Leukemia-Lymphoma 13 Leukemia 13 Carcinoma, Non-Small-Cell Lung 13 Lymphoma, Mantle-Cell 12 Stomach Neoplasms 10 Triple Negative Breast Neoplasms 7 Pancreatic Neoplasms 7 Ovarian Neoplasms 7 Neoplasm Metastasis 7 Uterine Cervical Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 6 Myelodysplastic Syndromes 6 Lymphoma, B-Cell, Marginal Zone 6 Head and Neck Neoplasms 6 Carcinoma, Renal Cell 6 Breast Neoplasms 6 Melanoma 5 Liposarcoma, Myxoid 5 Colorectal Neoplasms 5 Burkitt Lymphoma 5

Interventions

fludarabine 1 Influenza Vaccines 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07502287 2026-03-30

DUAL-NK-NB

Beijing Biotech

Phase 1/2 Recruiting

Neuroblastoma, Recurrence, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡